Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

NanoValent promotes Mark Lewis to COO

He will also continue to manage the group’s business operations

- PMLiVE

Can biosimilars live up to the hype?

Carol Lynch, chair of the European Generic Medicines Association, wants new biosimilars therapies to become routine

- PMLiVE

AstraZeneca embarks on oncology research access project

Invites companies to join molecular data resource consortium

Immunotherapy in oncology

Consultant David Cooney explores the medical insights, unmet needs, and future of the vastly growing area of immunotherapy as the fourth pillar in oncology.

Blue Latitude Health

- PMLiVE

Amgen enters into $540m immunotherapy collaboration

Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO

- PMLiVE

Novo Nordisk’s Tresiba gaining ground in basal insulin market

Delivers $216m this year despite ICER's report of insufficient data to favour the drug over Sanofi's Lantus

- PMLiVE

European prostate cancer treatment is changing – what are the opportunities for marketers?

Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe and how the recent trends impact the opportunities available to healthcare marketers.

Blue Latitude Health

- PMLiVE

Healthcare at Home promotes Prof Sir Jonathan Asbridge

He takes up the role of clinical director

Novartis Gehry Building

NICE backs Cosentyx for ankylosing spondylitis

The immunotherapy is on course to be “one of the most successful launches in Novartis history”

- PMLiVE

Immunotherapy and future directions in oncology

How the field of cancer drugs is expanding as technology improves

- PMLiVE

Teva acquires Allergan’s generics operations in $38.8bn deal

Also discloses $500m agreement to purchase the Irish firm’s distribution business

- PMLiVE

Polleo Pharma co-founders join Chronos Therapeutics

Dr Fraser Murray and Dr Timonthy Schulz-Utermoehl become pre-clinical development VPs

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links